Early Efficacy With Mosunetuzumab Appears Promising for Follicular and Other Lymphomas
Elizabeth L. Budde, MD, PhD, discusses the interim efficacy results form the phase I study of mosunetuzumab in patients with lymphomas.
Elizabeth L. Budde, MD, PhD, assistant professor in department of hematology at City of Hope, discusses the interim efficacy results from a phase I study of mosunetuzumab in patients with lymphomas.
While this data is still early, Budde says the efficacy results are encouraging. In patients with follicular lymphoma, there was a 69% overall response rate (ORR) and 40% of patients achieved complete response (CR). For diffuse large B-cell lymphoma, the ORR was up to 40% with a 19% CR rate.
In the patients who achieved CR, only 1 relapsed, Budde says. However, the patient received a second treatment and went into a complete remission again. The patients have been followed for close to 300 days, with some of the longest patients closer to 2 years in remission.
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Enasidenib Shows Promise as Post-Transplant Maintenance in IDH2-Mutated AML
January 7th 2025Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated acute myeloid leukemia treatment.
Read More
Telehealth Continues to Show Importance Post COVID-19 in Rare Diseases
December 29th 2024In an interview with Peers & Perspectives in Oncology, Doris M. Ponce, MD, MS, a bone marrow transplant specialist, discussed how telehealth made a significant impact on patients with rare diseases receiving medical care and why the rules from the COVID-19 era should be brought back to continue helping these patients.
Read More
